Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 2/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | MAX | P61244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137809 | 0.89 | EP300 (0.54) | EP300LNPEPTP53MDM2LMNA | |
| SCHEMBL17775433 | 0.86 | MYC (0.54) | EP300LMNAHPGDBRD4MYC | |
| SCHEMBL16392534 | 0.85 | EP300 (0.48) | EP300LNPEPLMNAHPGDBCL2 | |
| SCHEMBL16392500 | 0.84 | EP300 (0.52) | EP300LNPEPLMNAHPGDBCL2 | |
| SCHEMBL19608160 | 0.81 | EP300 (0.50) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16369635 | 0.79 | MYC (0.62) | EP300BRD4MYCMAX | |
| SCHEMBL16392547 | 0.77 | EP300 (0.48) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16369610 | 0.77 | EP300 (0.63) | EP300LMNABCL2BCL2L1MCL1 | |
| SCHEMBL19608100 | 0.76 | EP300 (0.49) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16371049 | 0.76 | MAPT (0.48) | EP300LMNABCL2BCL2L1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-20200331964-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-10793600-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145304-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, CBS | EP300 3526/4885LNPEP 6/4885TP53 3832/4885 |
| US-11225503-B2 | Crystobactamides | PKD2, SLC7A11, CTH | EP300 4199/4885LNPEP 146/4885TP53 4725/4885 |
| US-20190185514-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | EP300 3359/4885LNPEP 35/4885TP53 4203/4885 |
| US-20200331964-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | EP300 3416/4885LNPEP 21/4885TP53 4413/4885 |
| US-10793600-B2 | Cystobactamides | CTH, SLC7A11, SULT2A1 | EP300 3514/4885LNPEP 42/4885TP53 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.